antibody discovery

A-Alpha Bio is a Seattle-based biotechnology company founded in 2017 at the University of Washington's Institute for Protein Design and Center for Synthetic Biology. It harnesses synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions, using its AlphaSeq experimental platform and AlphaBind computational platform for in-house therapeutic programs and partnerships with pharmaceutical companies.

binding prediction from protein sequencehigh-throughput protein-protein interaction measurementmachine learningprotein interface engineeringsynthetic biology

AbbraTech is a life science company founded in 2020 in Branford, Connecticut, by experienced life science industry researchers. Its mission is to enable discovery of antibodies against drug targets beyond the reach of conventional approaches. Its EPIVOLVE technology is a generalizable platform capable of driving antibody recognition of any exposed region of a target protein, regardless of the underlying sequence. The company works with industry and academic partners to discover next-generation medicines.

antibody engineeringantibody validationB cell cloningimmunorepertoire analysisphage display

Abterra Biosciences is enabling the next-generation of antibody therapeutics. Its technologies use next-generation sequencing, mass spectrometry, and machine learning methods to comprehensively map the antibody response to challenge. The company began as Digital Proteomics LLC, a spin-out of the University of California – San Diego, founded by professors Pavel Pevzner and Vineet Bafna.

antibody sequencingB-cell receptor sequencingBioinformaticsmachine learningmass spectrometrynext-generation sequencing

Abzena is a fully integrated biologics and bioconjugates CDMO+CRO, founded in 2001, providing discovery through commercial services for antibodies, ADCs, AOCs, RDCs, vaccines, fusion proteins, bispecifics and other complex biologics. It operates integrated facilities in San Diego CA, Bristol PA, and Cambridge UK, with corporate headquarters in Raleigh, North Carolina, and has partnered with over 500 customers globally.

analytics and bioassaysbioconjugationcell line developmentcGMP manufacturingcomplex chemistryformulation developmentHPAPI handlingimmunogenicity testingprocess developmentprotein engineeringtechnology transfer

Abzyme Therapeutics is a biopharmaceutical discovery and service company located outside Philadelphia, specializing in modular antibody discovery and conditionally-active antibody engineering for immunotherapy using proprietary antibody generation and optimization platforms based on yeast-display, self-diversifying libraries and FACS single-cell sorting. The company has over 60 therapeutic and diagnostic assets in development for infectious diseases, cancer, ophthalmology, inflammation and central nervous system disorders.

affinity maturationantibody humanizationantibody optimizationbispecific antibody generationELISAFACS single-cell sortingFlow Cytometryimmunohistochemistryllama immunizationsurface plasmon resonanceWestern blottingyeast display

Æona Pharmaceuticals is a biopharmaceutical company based in San Diego, CA, focused on developing human antibody therapeutics. It is advancing the antibody therapeutic AE-101 to address Rhabdomyosarcoma (RMS) and Malignant Fibrous Histiocytoma (MFH). The company uses an AI-driven antibody engineering platform combining computational protein design, in silico screening, and wet lab techniques to develop targeted biological therapeutics.

AI and machine learning drug discoveryantibody engineeringcomputational protein designin silico screeningwet lab engineering

Alchemab Therapeutics has developed a platform that identifies novel drug targets and therapeutics by analyzing patient antibody repertoires. Using well-defined patient samples, deep B cell sequencing, and computational analysis, it identifies convergent protective antibody responses among individuals resilient to specific diseases. It is building a pipeline of protective therapeutics for hard-to-treat diseases, initially focused on neurodegenerative conditions and oncology.

clinical developmentCMCcomputational analysisdeep B cell sequencingdeep learningpre-clinical developmenttoxicology

Antibody Solutions helps biopharmaceutical companies advance their discovery of better diagnostics and therapeutics by delivering fit-for-purpose antibodies. With more than 30 years of history, the company provides antibody discovery and production services under a fee-for-service, pay-as-you-go model that keeps client IP in their hands.

affinity purificationantibody manufacturingantigen developmentassay developmentB-cell fusionbioconjugationFlow Cytometryhybridoma generationmolecular modelingmonoclonal antibody discoverypolyclonal antibody discoverysequencing

AvantGen is a San Diego-based biotechnology company that enables scientific partners in the discovery and optimization of novel antibody drugs. It uses a proprietary yeast display system and its Germliner™ Library Collection to provide fully human antibody platforms with more than 100 billion antibody clones, and offers affinity maturation and antibody engineering services.

affinity maturationantibody engineeringbioconjugationcell sorting based screeninglibrary designQCrabbit monoclonal antibody generationrecombinant expression in HEK293 or CHO cellsyeast display

AVS Bio is a USDA-licensed biologics manufacturer and supplier of avian biological materials and antibody discovery services for biopharmaceutical companies, diagnostic developers, and research institutions. Since 1961, it has provided SPF eggs, antigens, recombinant proteins, custom antibodies, and primary chicken cell products, supporting vaccines, therapeutics, diagnostics, and environmental testing worldwide.

9 CFR testingagar gel precipitin testsantibody developmentcustom assay developmentELISAhemagglutination inhibition assaysIgY antibody productionindirect fluorescent antibody testingmicroneutralization testsPCR testingserum neutralization testsserum plate agglutinationvirus production

Biocytogen is a global provider of animal and cell model generation for preclinical research, offering gene-edited and humanized mouse models, cell lines, and integrated drug discovery services. Through its BioMice brand it supplies off-the-shelf and custom animal models, and it develops fully human antibody discovery platforms including the RenMice family (RenMab, RenLite, RenNano, RenTCRmimic, RenMice KO) based on its SUPCE gene-editing technology.

colony management and breedingcryopreservationgene editinghumanized mouse modelsin vitro pharmacologyin vivo pharmacologyknockout/knockin mouse model generationnon-GLP toxicity studiesPK/PD studiesrederivation

Carterra is a provider of high-throughput screening and characterization technology for drug discovery, combining patented microfluidics with real-time High Throughput Surface Plasmon Resonance (HT-SPR) instruments, consumables, and Kinetic and Epitope Analysis and Visualization Software. Founded in 2005 as Wasatch Microfluidics, the company is headquartered in Salt Lake City, Utah.

epitope binningepitope mappingfragment screeninghigh throughput kineticsHigh Throughput Surface Plasmon Resonance (HT-SPR)label-free biomolecular screening and characterizationmicrofluidics

IgGenix, Inc. is a clinical-stage antibody discovery and development company with a mission to solve allergies and other immunological diseases. Using its SEQ SIFTER™ single cell RNA-sequencing-based discovery platform, it captures rare human B cells that produce IgE antibodies from human blood and re-engineers fully human, high-affinity, allergen-specific IgG antibodies designed to block the allergic cascade. Its lead candidate IGNX001 targets peanut allergy and has completed a Phase 1 clinical trial.

antibody developmentantibody re-engineeringclinical trialsobservational studiessingle cell RNA-sequencing

Integral Molecular is a research-driven biotechnology company creating innovative technologies and therapeutic antibodies for under-exploited membrane protein targets, including GPCRs, ion channels, transporters, and viral envelopes. Founded in 2001, it has developed 6 novel technology platforms and provides services such as antibody specificity screening, target identification, epitope mapping, and antibody discovery.

Ala-scan epitope mappingantibody specificity screeningCDR-scanningcell and molecular biologyepitope mappingFlow Cytometryhigh-throughput instrumentationroboticstarget identification